Your browser doesn't support javascript.
loading
Exposure of human immune cells, to the antiretrovirals efavirenz and lopinavir, leads to lower glucose uptake and altered bioenergetic cell profiles through interactions with SLC2A1.
Heaton, Bethany J; Jensen, Rebecca L; Line, James; David, Christopher A W; Brain, Danielle E; Chadwick, Amy E; Liptrott, Neill J.
Afiliação
  • Heaton BJ; Immunocompatibility Group, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, The University of Liverpool, Liverpool, UK; Centre of Excellence for Long-Acting Therapeutics (CELT), Department of Pharmacology and Therapeutics, Institute of Systems, Mo
  • Jensen RL; Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, The University of Liverpool, Liverpool, UK.
  • Line J; Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, The University of Liverpool, Liverpool, UK.
  • David CAW; Immunocompatibility Group, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, The University of Liverpool, Liverpool, UK; Centre of Excellence for Long-Acting Therapeutics (CELT), Department of Pharmacology and Therapeutics, Institute of Systems, Mo
  • Brain DE; Immunocompatibility Group, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, The University of Liverpool, Liverpool, UK; Centre of Excellence for Long-Acting Therapeutics (CELT), Department of Pharmacology and Therapeutics, Institute of Systems, Mo
  • Chadwick AE; Centre for Drug Safety Science, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, The University of Liverpool, Liverpool, UK.
  • Liptrott NJ; Immunocompatibility Group, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular and Integrative Biology, The University of Liverpool, Liverpool, UK; Centre of Excellence for Long-Acting Therapeutics (CELT), Department of Pharmacology and Therapeutics, Institute of Systems, Mo
Biomed Pharmacother ; 150: 112999, 2022 Jun.
Article em En | MEDLINE | ID: mdl-35461087
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 Problema de saúde: 2_enfermedades_transmissibles Assunto principal: Infecções por HIV / Fármacos Anti-HIV Limite: Humans Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Macau
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 2_ODS3 Problema de saúde: 2_enfermedades_transmissibles Assunto principal: Infecções por HIV / Fármacos Anti-HIV Limite: Humans Idioma: En Revista: Biomed Pharmacother Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Macau